spacer
home > ict > autumn 2008 > more than a lifestyle drug
PUBLICATIONS
International Clinical Trials

More than a Lifestyle Drug

Urological diseases or dysfunctions will afflict most of us at some point in our adult lives and will have a severe negative impact on quality of life. Urological conditions range from common ‘bothersome’ complaints such as urinary incontinence, benign prostatic hyperplasia (BPH) and male sexual dysfunction, profoundly uncomfortable and painful conditions such as kidney stones and interstitial cystitis, and life-threatening prostate, bladder and kidney cancers.

The underlying aetiology of certain urological diseases is well understood and has resulted in the introduction of several ‘blockbuster’ drugs during the last decade designed for the treatment of overactive bladder (OAB), BPH and erectile dysfunction. Few effective pharmaceutical remedies are available for more complex urological conditions such as stress urinary incontinence, premature ejaculation, chronic prostatitis and interstitial cystitis.

Current urological drug development is attempting to address these significant unmet or poorly met medical needs, and to bring more effective and better tolerated...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mike Wyllie has over 25 years of experience in senior management level positions within the pharmaceutical industry. He started out as Director of Biology at Pfizer from 1984-1998. Subsequently, he established Urodoc Ltd, a strategic planning and medical education company servicing the pharmaceutical industry. In 2003, he co-founded Plethora Solutions Ltd, a company specialising in IP generation, urological and andrological drug development and Phase II clinical trials. He is also a non-executive Director and CSO of the medical technology company Zi Medical Plc. In 2006 Mike became founding partner of Global Pharma Consulting Ltd, which provides interim management support across a wide range of functions to medium and small biopharmaceutical and medical technology companies. In December 2006 he helped to float the Chinese pharmaceutical company Taihua (AIM:TAIH) and joined the boards of Bactomed Ltd and Bluescope Ltd. Mike is named inventor on over 100 methods of treatment, formulation and device patents.
spacer
Mike Wyllie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera’s preservative-free multi-dose eyedropper approved in Brazil for Aché’s NSAID’s and Dry Eye formulations

La Verpillière, France São Paulo, Brazil May 5, 2021 – Nemera is excited to announce that its multidose eye dropper Novelia® has been approved by ANVISA for the preservative-free formulations CLILON [1] (Ketorolac 0,4% and 0,5%), a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat moderately severe pain and inflammation, usually after surgery.
More info >>

White Papers

Smaller, Smarter, Electronic, Connected: The Next Generation of Drug-Delivery Devices

Phillips-Medisize

An exciting trend in drug delivery is underway: the movement toward smaller, smarter, wirelessly connected electronic devices that allow patient-administered therapy. Inspired by the technological advancements driving the consumer electronics market, new methods for drug delivery show great promise for all stakeholders. Patients wishing to claim more autonomy over their drug regimens, caregivers and medical professionals wanting to more closely monitor drug compliance, health insurance organizations looking to keep costs down, and developers of pharmaceutical products interested in conducting better managed clinical trials can all benefit from these novel, next-generation technologies.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement